Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 17, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the lives of patients who have undergone surgery for rectal cancer and are experiencing Low Anterior Resection Syndrome (LARS) symptoms. LARS can cause issues like bowel problems and affect a person's overall quality of life after surgery. The main goal of the study is to see if a more intensive follow-up program, which includes regular check-ups, medical treatments, and special exercises for pelvic floor muscles, can help improve these symptoms and enhance quality of life. Researchers will compare results from patients who receive this enhanced follow-up care to those who do not, to determine if the program is effective.
To be eligible for this trial, participants need to be at least 18 years old and have had a specific type of rectal cancer surgery. They should be able to understand and sign consent forms. However, those with certain mental health conditions or who cannot have their stoma reversed due to complications will not be included. The trial is not yet recruiting participants, but it aims to provide valuable insights for better care and support for patients dealing with LARS after their surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients older than 18 years
- • patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy
- • able to give informed consent as documented by signature
- Exclusion Criteria:
- • dementia or other psychiatric disorder that would prevent the patients from answering the questionnaires and experiencing sustainable training effects
- • impossibility of stoma reversal due to persistent anastomotic leak and/or local recurrence
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Winterthur, , Switzerland
Basel, , Switzerland
Bern, , Switzerland
Bern, , Switzerland
Patients applied
Trial Officials
Daniel Steinemann, Deputy chief physician
Study Chair
Clarunis - Universitäres Bauchzentrum Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported